Scholarlink

Objective <p>To assess the efficacy of two autologous platelet-rich plasma injections (PRP) in treating late-stage knee osteoarthritis and their effects on joint pain, stiffness and function as well as serum biomarkers reflecting inflammation, and cartilage turnover.</p> Methods <p>Ninety patients (aged 40–80 years) with symptomatic KL 3–4 KOA on arthroplasty waiting lists were randomized to PRP (two injections one week apart) and CS (a single injection of betamethasone), or NSAID (aceclofenac tablets) as the control groups. Primary outcomes included VAS pain scores, WOMAC scores, opioid use, and serum biomarkers (COMP, MMP-3, CGRP, CCL2, VEGF, IL-6, IL-18, TNF-α, CX3CL1, sTREM2, sRAGE, TGF-β1, BDNF) were measured at baseline, 3 months, and 6 months.</p> Results <p>Eighty-two patients completed the 6-month follow-up. Baseline characteristics (VAS, WOMAC) were comparable among the groups. PRP treatment resulted in significant and sustained reductions in VAS pain scores at 3 and 6 months compared with those at baseline (<i>p</i> &lt; 0.001) and in both control groups (3 months: <i>p</i> &lt; 0.001 vs. CS and NSAID; 6 months: <i>p</i> = 0.004 vs. CS; <i>p</i> = 0.002 vs. NSAID). WOMAC total and subscale scores (pain, stiffness, function) improved significantly only in the PRP group at both follow-up points (all <i>p</i> ≤ 0.03), with significant intergroup differences favoring PRP. Opioid consumption was significantly lower in the PRP group than in the CS and NSAID groups at 3 months (<i>p</i> = 0.002 and <i>p</i> = 0.025, respectively) and than in the CS group at 6 months (<i>p</i> = 0.006). At 3 months, PRP significantly reduced levels of proinflammatory and cartilage degradation biomarkers (COMP, MMP-3, IL-6, IL-18, TNF-α) and CGRP compared with controls, while increasing levels of anti-inflammatory markers (sTREM2, sRAGE, TGF-β1). Several effects were maintained at 6 months, including continued reductions in COMP, IL-6, and IL-18 levels compared with the CS group and in IL-6 and TNF-α levels compared with the NSAIDs group. No significant changes were observed in MCP-1, VEGF, CX3CL1, BDNF, or β-NGF. Adverse events were mild and transient in the PRP group.</p> Conclusion <p>Two PRP injections demonstrated greater 6-month clinical and biomarker improvements compared to CS and NSAIDs in late-stage KOA, supporting PRP as a safe bridge therapy prior to arthroplasty.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intra-articular platelet-rich plasma demonstrates superior clinical and serum biomarker outcomes compared with corticosteroids and NSAIDs in late-stage knee osteoarthritis: a randomised controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Marek Lacko,
  • Omar Awad,
  • Martin Matúška,
  • Michal Strážik,
  • Juraj Barej,
  • Vladimír Filip,
  • Lucia Slovinská,
  • Jana Matejová,
  • Denisa Harvanová

摘要

Objective

To assess the efficacy of two autologous platelet-rich plasma injections (PRP) in treating late-stage knee osteoarthritis and their effects on joint pain, stiffness and function as well as serum biomarkers reflecting inflammation, and cartilage turnover.

Methods

Ninety patients (aged 40–80 years) with symptomatic KL 3–4 KOA on arthroplasty waiting lists were randomized to PRP (two injections one week apart) and CS (a single injection of betamethasone), or NSAID (aceclofenac tablets) as the control groups. Primary outcomes included VAS pain scores, WOMAC scores, opioid use, and serum biomarkers (COMP, MMP-3, CGRP, CCL2, VEGF, IL-6, IL-18, TNF-α, CX3CL1, sTREM2, sRAGE, TGF-β1, BDNF) were measured at baseline, 3 months, and 6 months.

Results

Eighty-two patients completed the 6-month follow-up. Baseline characteristics (VAS, WOMAC) were comparable among the groups. PRP treatment resulted in significant and sustained reductions in VAS pain scores at 3 and 6 months compared with those at baseline (p < 0.001) and in both control groups (3 months: p < 0.001 vs. CS and NSAID; 6 months: p = 0.004 vs. CS; p = 0.002 vs. NSAID). WOMAC total and subscale scores (pain, stiffness, function) improved significantly only in the PRP group at both follow-up points (all p ≤ 0.03), with significant intergroup differences favoring PRP. Opioid consumption was significantly lower in the PRP group than in the CS and NSAID groups at 3 months (p = 0.002 and p = 0.025, respectively) and than in the CS group at 6 months (p = 0.006). At 3 months, PRP significantly reduced levels of proinflammatory and cartilage degradation biomarkers (COMP, MMP-3, IL-6, IL-18, TNF-α) and CGRP compared with controls, while increasing levels of anti-inflammatory markers (sTREM2, sRAGE, TGF-β1). Several effects were maintained at 6 months, including continued reductions in COMP, IL-6, and IL-18 levels compared with the CS group and in IL-6 and TNF-α levels compared with the NSAIDs group. No significant changes were observed in MCP-1, VEGF, CX3CL1, BDNF, or β-NGF. Adverse events were mild and transient in the PRP group.

Conclusion

Two PRP injections demonstrated greater 6-month clinical and biomarker improvements compared to CS and NSAIDs in late-stage KOA, supporting PRP as a safe bridge therapy prior to arthroplasty.